Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 803Uterine Cervical Neoplasms 541Endometrial Neoplasms 462Breast Neoplasms 222Fallopian Tube Neoplasms 198Colorectal Neoplasms 180Carcinoma, Non-Small-Cell Lung 162Neoplasms 138Stomach Neoplasms 126Pancreatic Neoplasms 119Prostatic Neoplasms 109Melanoma 108Neoplasm Metastasis 107Lung Neoplasms 104Carcinoma, Ovarian Epithelial 93Triple Negative Breast Neoplasms 91Squamous Cell Carcinoma of Head and Neck 82Head and Neck Neoplasms 76Esophageal Neoplasms 76Urinary Bladder Neoplasms 74Carcinoma, Renal Cell 74Uterine Neoplasms 66Vulvar Neoplasms 64Colonic Neoplasms 59Carcinoma, Hepatocellular 59Peritoneal Neoplasms 58Uterine Cervical Dysplasia 57Sarcoma 52Carcinoma, Transitional Cell 49Papillomavirus Infections 47

Interventions

Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Cancer Recurrent × Gynecologic × 1 year × Clear all
NCT04030429 2025-07-16

Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

National Cheng-Kung University Hospital

Phase 2 Terminated
40 enrolled
Gynecologic

Endometrial Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡